Pier Leopoldo Capecchi

List of Publications by Year
in descending order

51 papers	2,017 citations	331670 21 h-index	243625 44 g-index
51 all docs	51 docs citations	51 times ranked	2688 citing authors

#	Article	IF	Citations
1	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases. Scientific Reports, 2022, 12, 1075.	3.3	11
2	Transient Hypogonadism Is Associated With Heart Rateâ€“Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men. Journal of the American Heart Association, 2022, 11, e023371.	3.7	6
3	Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19. Nature Reviews Immunology, 2022, 22, 270-272.	22.7	32
4	Anti-Ca _v 1.2 Antibodyâ€“Induced Atrioventricular Block as a Novel Form in the Adult: Long-Term Pacemaker-Sparing Activity of Hydroxychloroquine. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	4.8	2
5	Antirheumatic agents in covid-19: is IL-6 the right target?. Annals of the Rheumatic Diseases, 2021, 80, e2-e2.	0.9	15
6	Worldwide Survey of COVID-19â€“Associated Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009458.	4.8	127
7	Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy. International Journal of Environmental Research and Public Health, 2021, 18, 3875.	2.6	0
8	Drug-Associated QTc Prolongation in Geriatric Hospitalized Patients: A Cross-Sectional Study in Internal Medicine. Drugs - Real World Outcomes, 2021, 8, 325-335.	1.6	6
9	Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010042.	4.8	8
10	Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. Frontiers in Medicine, 2021, 8, 730161.	2.6	8
11	Comment on â€œAutoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?â€. Journal of Hepatology, 2021, 75, 994-995.	3.7	11
12	Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokineâ€Mediated Inhibition of Connexin43 Expression. Journal of the American Heart Association, 2021, 10, e022095.	3.7	10
13	Epidemiological and virological surveillance of Severe Acute Respiratory Infections in the 2019/2020 season in Siena, Tuscany, Italy.. Journal of Preventive Medicine and Hygiene, 2021, 62, E782-E788.	0.9	1
14	Cardiac Arrest Risk During Acute Infections. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008627.	4.8	44
15	Targeting IL-6 in COVID-19. Response to: â€˜Rational use of tocilizumab in COVID-19â€™ by Jain and Sharma. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-218627.	0.9	1
16	IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008791.	4.8	17
17	Letter by Lazzerini et al Regarding Article, â€œAutoantibody Signature in Cardiac Arrestâ€. Circulation, 2020, 142, e370-e371.	1.6	1
18	Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Frontiers in Pharmacology, 2020, 11, 684.	3.5	13

#	Article	IF	Citations
19	COVID-19 Sepsis and Microcirculation Dysfunction. Frontiers in Physiology, 2020, 11, 747.	2.8	79
20	COVID-19, Arrhythmic Risk, and Inflammation. Circulation, 2020, 142, 7-9.	1.6	219
21	Inflammatory cytokines, life-threatening arrhythmias and premature mortality in chronic inflammatory arthritis: time to focus on. Annals of the Rheumatic Diseases, 2019, 78, e98-e98.	0.9	4
22	Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukinâ€6â€“Mediated Changes in Connexin Expression. Journal of the American Heart Association, 2019, 8, e011006.	3.7	94
23	Autoimmune Calcium Channelopathies and Cardiac Electrical Abnormalities. Frontiers in Cardiovascular Medicine, 2019, 6, 54.	2.4	17
24	Autoimmune and inflammatory K+ channelopathies in cardiac arrhythmias: Clinical evidence and molecular mechanisms. Heart Rhythm, 2019, 16, 1273-1280.	0.7	18
25	Commentary: Systemic effects of IL-17 in inflammatory arthritis. Frontiers in Cardiovascular Medicine, 2019, 6, 183.	2.4	6
26	Cardioimmunology of arrhythmias: the role of autoimmuneÂand inflammatory cardiacÂchannelopathies. Nature Reviews Immunology, 2019, 19, 63-64.	22.7	108
27	Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies. Journal of the American Heart Association, 2018, 7, e010595.	3.7	72
28	Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PLoS ONE, 2018, 13, e0208321.	2.5	105
29	Torsades de Pointes in Patients with Polymyalgia Rheumatica. Current Pharmaceutical Design, 2018, 24, 323-340.	1.9	10
30	Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. European Heart Journal, 2017, 38, ehw208.	2.2	203
31	Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. Nature Reviews Cardiology, 2017, 14, 521-535.	13.7	82
32	Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart, 2017, 103, 1821-1829.	2.9	90
33	Autoimmune cardiac channelopathies: the heart of the matter. Nature Reviews Cardiology, 2017, 14, 566-566.	13.7	4
34	Adenosine receptors expression in cardiac fibroblasts of patients with left ventricular dysfunction due to valvular disease. Journal of Receptor and Signal Transduction Research, 2017, 37, 283-289.	2.5	3
35	Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. Immunologic Research, 2017, 65, 262-275.	2.9	14
36	Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Design, Development and Therapy, 2016, Volume 10, 3083-3098.	4.3	17

#	Article	IF	Citations
37	Marked QTc Prolongation and Torsades de pointes in Patients with Chronic Inflammatory Arthritis. Frontiers in Cardiovascular Medicine, 2016, 3, 31.	2.4	20
38	Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003419.	4.8	55
39	Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls. Lupus Science and Medicine, 2016, 3, e000189.	2.7	9
40	Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome. Cardiac Electrophysiology Clinics, 2016, 8, 373-384.	1.7	22
41	Isolated atrioventricular block of unknown origin in the adult and autoimmunity: diagnostic and therapeutic considerations exemplified by 3 anti-Ro/SSAâ€“associated cases. HeartRhythm Case Reports, 2015, 1, 293-299.	0.4	14
42	Long QT Syndrome: An Emerging Role for Inflammation and Immunity. Frontiers in Cardiovascular Medicine, 2015, 2, 26.	2.4	133
43	Comment on â€œAbsence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patientsâ€• Seminars in Arthritis and Rheumatism, 2015, 44, e16-e17.	3.4	7
44	The role of P2X7 receptors in tissue fibrosis: a brief review. Purinergic Signalling, 2015, 11, 435-440.	2.2	33
45	Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans. International Immunopharmacology, 2015, 24, 276-284.	3.8	15
46	Isolated atrioventricular block of unknown origin in adults and anti-Ro/SSA antibodies: Clinical evidence, putative mechanisms, and therapeutic implications. Heart Rhythm, 2015, 12, 449-454.	0.7	27
47	Antiarrhythmic Potential of Anticytokine Therapy in Rheumatoid Arthritis: Tocilizumab Reduces Corrected QT Interval by Controlling Systemic Inflammation. Arthritis Care and Research, 2015, 67, 332-339.	3.4	85
48	Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmunity Reviews, 2014, 13, 936-944.	5.8	75
49	Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. Journal of Rheumatology, 2008, 35, 1958-65.	2.0	24
50	Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients. Transplant International, 2005, 18, 289-295.	1.6	6
51	Upregulation of A2A adenosine receptor expression by TNF-Î± in PBMC of patients with CHF: a regulatory mechanism of inflammation. Journal of Cardiac Failure, 2005, 11, 67-73.	1.7	34